Literature DB >> 29920893

Roles of Albumin-Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery.

Pengfei Zhao1,2, Yonghui Wang1, Aihua Wu1, Yuefeng Rao3, Yongzhuo Huang1,4.   

Abstract

Nutrient transporters have attracted significant attention for their promising application in biomimetic delivery. Due to the active consumption of nutrients, cancer cells generally overexpress nutrient transporters to meet their increased need for energy and materials. For example, albumin-binding proteins (ABPs) are highly overexpressed in malignant cells, stromal cells, and tumor vessel endothelial cells responsible for albumin uptake. ABP (e.g., SPARC) is a promising target for tumor-specific drug delivery, and albumin has been widely used as a biomimetic delivery carrier. Apart from the transportation function, ABPs are closely associated with neoplasia, invasion, and metastasis. Herein, a summary of the roles of ABP in cancer progression and the application of albumin-based biomimetic tumor-targeted delivery through the ABP pathway is presented.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  albumin-binding proteins; biomimetic delivery; cancer; drug delivery; nutrient transporters

Mesh:

Substances:

Year:  2018        PMID: 29920893     DOI: 10.1002/cbic.201800201

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  10 in total

1.  Remodeling "cold" tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona.

Authors:  Yang He; Yuefei Fang; Meng Zhang; Yuge Zhao; Bin Tu; Mingjie Shi; Bahtiyor Muhitdinov; Akmal Asrorov; Qin Xu; Yongzhuo Huang
Journal:  Acta Pharm Sin B       Date:  2021-09-30       Impact factor: 14.903

2.  Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma.

Authors:  Ling Wang; Wei Wang; Yangchun Xu; Qiang Wang
Journal:  Onco Targets Ther       Date:  2020-11-11       Impact factor: 4.147

Review 3.  Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation.

Authors:  Hanhee Cho; Seong Ik Jeon; Cheol-Hee Ahn; Man Kyu Shim; Kwangmeyung Kim
Journal:  Pharmaceutics       Date:  2022-03-28       Impact factor: 6.525

4.  Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin.

Authors:  Mateusz P Czub; Adam M Boulton; Ettore J Rastelli; Nikhil R Tasker; Taber S Maskrey; Isabella K Blanco; Kelley E McQueeney; John H Bushweller; Wladek Minor; Peter Wipf; Elizabeth R Sharlow; John S Lazo
Journal:  Mol Pharmacol       Date:  2020-09-25       Impact factor: 4.436

5.  Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel.

Authors:  Margaux Vigata; Christoph Meinert; Stephen Pahoff; Nathalie Bock; Dietmar W Hutmacher
Journal:  Polymers (Basel)       Date:  2020-02-24       Impact factor: 4.329

6.  Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen.

Authors:  Andrey S Drozdov; Petr I Nikitin; Julian M Rozenberg
Journal:  Int J Mol Sci       Date:  2021-12-01       Impact factor: 5.923

7.  Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy.

Authors:  Xiu Zheng; Xin Yu; Chenglong Wang; Yan Liu; Ming Jia; Fenting Lei; Ji Tian; Chunhong Li
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

8.  Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer.

Authors:  Xiao-Li Yu; Miao-Fang Wu; Lin Ding; Jin Yang; Shou-Min Bai
Journal:  Cancer Manag Res       Date:  2021-12-22       Impact factor: 3.989

Review 9.  Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy.

Authors:  Seong-Bin Yang; Nipa Banik; Bomin Han; Dong-Nyeong Lee; Jooho Park
Journal:  Pharmaceutics       Date:  2022-06-29       Impact factor: 6.525

10.  The Interaction of Temozolomide with Blood Components Suggests the Potential Use of Human Serum Albumin as a Biomimetic Carrier for the Drug.

Authors:  Marta Rubio-Camacho; José A Encinar; María José Martínez-Tomé; Rocío Esquembre; C Reyes Mateo
Journal:  Biomolecules       Date:  2020-07-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.